Key clinical point: Daily oral ivosidenib was associated with a complete response rate of nearly 32% and a low rate of serious adverse events in patients with IDH1-mutated relapsed/refractory acute myeloid leukemia (AML).
Major finding: Patients with complete responses had an 8.2-month duration of response, and a median overall survival of 18.8 months.
Study details: A phase 1 study including 179 patients who received 500 mg of ivosidenib daily.
Disclosures: Daniel A. Pollyea, MD, who presented the study, reported disclosures related to Abbvie, Agios, argenx, Celgene, Celyad, Curis, Pfizer, and Servier.
Source: Pollyea DA, et al. J Clin Oncol 36, 2018 (suppl) annual meeting of the American Society of Clinical Oncology; abstr 7000.
Pollyea DA, et al. J Clin Oncol 36, 2018 (suppl) annual meeting of the American Society of Clinical Oncology; abstr 7000.
This Week's Must Reads
First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.
President Trump requests $500 million for pediatric cancer, Trump D. State of the Union Address, Feb. 5, 2019.
Inadequate emergency care a challenge for rural pediatric patients, Walling EB et al. J Oncol Pract. 2019 Jan 31. doi: 10.1200/JOP.18.00115.
Must Reads in AML
IDH-mutated AML: First-line IDH inhibitors, chemo may up remission, Stein EM et al. ASH 2018, Abstract 560
Rapid genomic results possible, Beat AML trial suggests, Burd A et al. ASH 2018, Abstract 559
Phase 2 results for combo therapy in relapsed AML, Daver N et al. Cancer Discov. 2018 Nov 8. doi: 10.1158/2159-8290.CD-18-0774
Transcription factor networks in AML, Assi SA et al. Nat Genet. 2018 Nov 12. doi: 10.1038/s41588-018-0270-1
Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.